Search

Displaying results 2561 - 2570 of 9697 in total
  1. Drug

    Canosimibe

    go.drugbank.com/drugs/DB19723
    Investigational

    Canosimibe has a monoisotopic molecular weight of 809.43 Da. … Canosimibe is a small molecule drug.

  2. Drug

    Aftobetin

    go.drugbank.com/drugs/DB20425
    Investigational

    Aftobetin has a monoisotopic molecular weight of 452.23 Da. … Aftobetin is a small molecule drug.

  3. Drug

    Irampanel

    go.drugbank.com/drugs/DB21123
    Investigational

    Irampanel has a monoisotopic molecular weight of 309.15 Da. … Irampanel is a small molecule drug.

  4. Drug

    Rintodestrant

    go.drugbank.com/drugs/DB21472
    Investigational

    Rintodestrant has a monoisotopic molecular weight of 462.09 Da. … Rintodestrant is a small molecule drug.

  5. Drug

    Itruvone

    go.drugbank.com/drugs/DB21543
    Investigational

    Itruvone has a monoisotopic molecular weight of 296.21 Da. … Itruvone is a small molecule drug. Itruvone is under investigation in clinical trial NCT02322086 (A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10).

  6. Drug

    Azilsartan mopivabil

    go.drugbank.com/drugs/DB21569
    Experimental

    Azilsartan mopivabil has a monoisotopic molecular weight of 676.25 Da. … Azilsartan mopivabil is a small molecule drug.

  7. Drug

    Taragarestrant

    go.drugbank.com/drugs/DB21574
    Investigational

    Taragarestrant has a monoisotopic molecular weight of 474.13 Da. … Taragarestrant is a small molecule drug.

  8. Drug

    Salacetamide

    go.drugbank.com/drugs/DB20217
    Investigational

    Salacetamide has a monoisotopic molecular weight of 179.06 Da. … Salacetamide is a small molecule drug.

  9. Drug

    Riselcaftor

    go.drugbank.com/drugs/DB21685
    Experimental

    Riselcaftor has a monoisotopic molecular weight of 516.17 Da. … Riselcaftor is a small molecule drug.

  10. Drug

    Danvatirsen

    go.drugbank.com/drugs/DB14825
    Investigational

    Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).